Detalles de la búsqueda
1.
Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy.
Health Res Policy Syst
; 22(1): 74, 2024 Jul 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38956568
2.
Development and Pilot Test of the Registry Evaluation and Quality Standards Tool: An Information Technology-Based Tool to Support and Review Registries.
Value Health
; 25(8): 1390-1398, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35277336
3.
Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Value Health
; 24(5): 744-752, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33933244
4.
Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
Value Health
; 21(6): 698-706, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29909875
5.
IS THE EUNETHTA HTA CORE MODEL® FIT FOR PURPOSE? EVALUATION FROM AN INDUSTRY PERSPECTIVE.
Int J Technol Assess Health Care
; 34(5): 458-463, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334508
6.
Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
BMC Health Serv Res
; 16(1): 651, 2016 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-27842592
7.
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.
J Mark Access Health Policy
; 12(1): 21-34, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38544972
8.
The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire.
J Mark Access Health Policy
; 11(1): 2217543, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37284060
9.
How can a joint European health technology assessment provide an 'additional benefit' over the current standard of national assessments? : Insights generated from a multi-stakeholder survey in hematology/oncology.
Health Econ Rev
; 12(1): 30, 2022 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35652987
10.
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy.
Health Econ Rev
; 12(1): 54, 2022 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36333433
11.
Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.
Rheumatology (Oxford)
; 50(4): 756-61, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21149243
12.
Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.
Value Health
; 17(4): 307-9, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24968988
13.
Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.
Health Econ Rev
; 8(1): 24, 2018 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30242522
14.
"Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
Health Econ Rev
; 8(1): 23, 2018 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30229501
15.
Content comparison of health-related quality of life instruments for COPD.
Respir Med
; 101(6): 1113-22, 2007 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-17215114
16.
Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Clin Drug Investig
; 27(7): 469-79, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17563127
17.
Different Weights of the Evidence-Based Medicine Triad in Regulatory, Health Technology Assessment, and Clinical Decision Making.
Pharmaceut Med
; 31(4): 213-216, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28824273
18.
Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
Health Econ Rev
; 6(1): 46, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27687714
19.
[Costs of ambulatory care for RA patients in Germany]. / Arztkontaktpreise bei der ambulanten Versorgung der chronischen Polyarthritis in Deutschland.
Med Klin (Munich)
; 100(5): 255-61, 2005 May 13.
Artículo
en Alemán
| MEDLINE | ID: mdl-15902379
20.
Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
Drugs R D
; 15(3): 221-6, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26286202